HLA-A*02 in relation to outcome in human papillomavirus positive tonsillar and base of tongue cancer
Nikolaos Tertipis1, Lisa Villabona, Cecilia Nordfors
1Department of Oncology-Pathology, Karolinska Institutet, Cancer Center Karolinska, R8:01 Karolinska University Hospital, 171 76 Stockholm, Sweden. Tina.Dalianis@ki.se.
Background/Aim:
Patients with human papillomavirus (HPV)-positive tonsillar and base of tongue cancer have a better outcome than those with corresponding HPV-negative tumors (80% vs. 40% 5-year disease free survival with conventional radiotherapy). They should not all need chemoradiotherapy, but before tapering treatment, more markers are needed to predict treatment response. In the present study, human leukocyte antigen (HLA) - HLA-A*02 was analyzed with HPV as a prognostic factor for tonsillar and base of tongue cancer.
Patients And Methods:
Pre-treatment biopsies, previously tested for HPV DNA, from 425 patients diagnosed with tonsillar and base of tongue cancer between 2000-2009 at the Karolinska University Hospital were examined for HLA-A*02.
Results:
HLA-A*02 was present in 144/305 (47.2%) of the HPV-positive and 63/120 (52.8%) of the HPV-negative tumours. Among 383 patients treated with curative intent, absence of HLA-A*02 was correlated with increased disease-free survival in the HPV-positive (p=0.016), but not in the HPV-negative group.
Conclusion:
Absence of HLA-A*02 correlated with better disease-free survival for patients with HPV-positive tonsillar and base of tongue cancer.
